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Abstract
It is becoming increasingly apparent that cancer drug therapies can only reach their full potential
through appropriate patient selection. Matching drugs and cancer patients has proven to be a
complex challenge, due in large part to the substantial molecular heterogeneity inherent to human
cancers. This is not only a major hurdle to the improvement of the use of current treatments but
also for the development of novel therapies and the ability to steer them to the relevant clinical
indications. In this commentary we discuss recent studies from Kuo et al., published this month in
BMC Medicine, in which they used a panel of cancer cell lines as a model for capturing patient
heterogeneity at the genomic and proteomic level in order to identify potential biomarkers for
predicting the clinical activity of a novel candidate chemotherapeutic across a patient population.
The findings highlight the ability of a 'systems approach' to develop a better understanding of the
properties of novel candidate therapeutics and to guide clinical testing and application.
See the associated research paper by Kuo et al: http://www.biomedcentral.com/1741-7015/7/77
Commentary
The clinical benefit associated with virtually all cancer
drugs is typically limited to a fraction of treated patients.
Unfortunately, for most of these drugs, the basis for such
a variable response to treatment is poorly understood [1].
The recent emergence of so-called 'rationally-targeted'
agents, such as the kinase-targeted inhibitors, trastuzu-
mab (anti-HER2 antibody) and the small molecule kinase
inhibitors erlotinib (EGFR) and imatinib (BCR-ABL,
PDGFR and c-KIT), has led to significant insights into the
role of the genomic features of tumour cells in determin-
ing the clinical response to these treatments. It has also
highlighted the substantial heterogeneity that exists across
patient populations with respect to the tumour genome
[2-4]. For this class of inhibitors, activating mutations
affecting the kinase target have proven to be the most reli-
able predictors of drug response identified thus far [5-9].
Such findings have prompted substantial efforts to better
understand the relationship between specific tumour gen-
otypes and the clinical response to a variety of established
and investigational cancer drugs in order to prospectively
identify patient cohorts who are most likely to derive clin-
ical benefit from a particular therapeutic [10-14].
However, the identification of 'drug-sensitizing geno-
types' for the relatively non-specific conventional chemo-
therapy drugs has been more challenging. While these
agents still constitute the mainstay of first-line cancer drug
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therapy for many clinical indications, their precise mech-
anisms of action remain poorly understood which thus
challenges efforts to identify the specific genomic determi-
nants of variable treatment response. One approach to
this problem has been to interrogate the state of the
tumour genome more broadly by exploiting, for example,
genome-wide microarray-based expression profiling [15].
Such gene expression profiles, or signatures, can poten-
tially capture complex cellular states that are likely to
reflect a mixture of genomic features that vary between
tumours and which are associated with both mutational
and epigenetic distinctions [16]. Indeed, several such gene
signatures, for both predictive and prognostic assessment
of patient outcomes, have emerged from pre-clinical as
well as clinical studies and a few have now been approved
for clinical use [15,17,18]. In addition, a variety of addi-
tional forms of systems information, including genomic
copy number data, proteomic and phospho-proteomic
data, and, more recently, metabolomic information, can
all potentially be used to identify distinctions among
human tumours that relate to prognosis and treatment
response.
In the accompanying report published this month in BMC
Medicine, Kuo and coworkers present a systems analysis of
the sensitivity of a panel of human breast cancer-derived
cell lines to a polyamine analogue (PG-11047) currently
undergoing early phase clinical testing in cancer [19].
Polyamines are naturally present at relatively high con-
centrations in all cell types, where they are essential com-
ponents of nucleic acid metabolism and a variety of
fundamental cellular processes [20]. Since the enzymes
regulating polyamine synthesis and catabolism are fre-
quently dysregulated in human tumours, they have been
considered as potential targets for anti-cancer drug devel-
opment [21]. The authors had previously established and
characterized a collection of breast cancer cell lines as a
model system for examining therapeutic efficacy and its
relationship to specific genomic features [22]. Although
the validity of cell line-based approaches to inform clini-
cal decisions has been the subject of debate for many
years, such approaches have recently shown great poten-
tial in revealing the genomic basis of anti-cancer drug
response [22-26].
Using a panel of 48 genomically characterized human
breast cancer cell lines, Kuo et al. identified a set of 250
genes whose expression, as assessed by whole genome
microarray analysis, was associated with PG-11047 sensi-
tivity in an in vitro growth inhibition assay. Then, using a
bioinformatics tool called Ingenuity Pathway Analysis,
they found that this gene set was enriched for genes asso-
ciated with interferon response, suggesting that interferon
signalling might affect sensitivity to polyamine analogues.
This gene set was then further refined through a Monte
Carlo cross-validation approach to a list of 13 genes - a
manageable number with respect to the evaluation of
clinical specimens - and this 13 gene set was found to be
predictive of cell line sensitivity to PG-11047. The analysis
revealed several findings of potential interest. First, it was
observed that cell lines from the basal tumour subtype
were more sensitive to PG-11047 than cells from tumours
of luminal origin. By applying their classifier to a panel of
breast tumour samples, the authors observed that basal
tumours were, indeed, predicted to be more sensitive than
luminal tumours, suggesting that PG-11047 should
potentially be directed to patients with tumours of basal
subtype, which is the more aggressive tumour type.
Finally, they found that elevated levels of the cellular sur-
vival signalling protein, phospho-AKT, were associated
with increased PG-11047 sensitivity. Thus, the collective
analysis revealed several features of breast tumour cells
that may be relevant to their response to PG-11047.
This analysis nicely illustrates how the integration of mul-
tiple forms of system wide information with drug sensitiv-
ity profiles assessed in vitro using cancer-derived cell lines
can begin to penetrate the complexity of human tumours.
Recent advances in genomic and proteomic technologies
[27-29] have led to the establishment of increasingly com-
plex data sets; the use of computational modelling strate-
gies [30] to link such information to drug sensitivity
profiles has the potential to substantially enhance our
understanding of pharmacologic mechanisms. The ability
of the gene signature identified by Kuo et al. to facilitate
patient selection and to increase the likelihood of a posi-
tive clinical outcome remains to be tested. However, this
study constitutes a significant step towards the establish-
ment of genomic analysis as a broadly useful strategy for
stratifying patients for treatment with agents whose mech-
anism of action remains poorly understood.
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